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Objective: To define the benefit of sutureless and rapid deployment
valves in current minimally invasive approaches in isolated aortic
valve replacement.
Methods: A panel of 28 international experts with expertise in both
minimally invasive aortic valve replacement and rapid deployment
valveswas constituted.After thorough literature review, the experts rated
evidence-based recommendations in a modified Delphi approach.
Results: No guideline could be retrieved. Thirty-three clinical trials
and 9 systematic reviews could be identified for detailed text analysis
to obtain a total of 24 recommendations. After rating by the experts 12,
final recommendations were identified: preoperative computed to-
mographic scan as well as intraoperative transesophageal echocardi-
ography are highly recommended. Suitable annular sizes are 19 to
27 mm. There is a contraindication for bicuspid valves only for type
0 and for annular abscess or destruction due to infective endocarditis.
The use of sutureless and rapid deployment valves reduces extracor-
poreal circulation and aortic cross-clamp time and leads to less early
complications as prolonged ventilation, blood transfusion, atrial fi-
brillation, pleural effusions, paravalvular leakages and aortic regur-
gitation, and renal replacement therapy, respectively. These clinical
outcomes result in reduced intensive care unit and hospital stay and
reduced costs. The use of sutureless and rapid deployment valves will
lead to a higher adoption rate of minimally invasive approaches in
aortic valve replacement. Respect should be taken to a necessary short
learning curve for both sutureless and minimally invasive programs.
Conclusions: Sutureless and rapid deployment aortic valve re-
placement together with minimally invasive approaches offers an
attractive option in aortic valve placement for patients requiring bi-
ological valve replacement.
Key Words: Sutureless valves, Rapid deployment valves,
Minimally invasive surgery, Aortic stenosis.
(Innovations 2016;11:165Y173)
Isolated balloon valvuloplasty failed to mitigate the gravenatural course of aortic valve stenosis with mortality rates of
70% at 1 year.1 Most patients with symptomatic aortic valve
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stenosis therefore require replacement of the valve,2 currently
most often facilitated by full median sternotomy representing the
standard approach.With an increasing rate of elderly people due to
demographic changes in western societies, risk profiles of patients
requiring elective or urgent aortic valve replacement have sub-
sequently changed.3 Transcatheter approaches have emerged in
the last years for high-risk patients with the attempt to avoid both
sternotomy and extracorporeal circulation as well as myocardial
ischemia due to cross-clamping of the aorta.4 However, because
the diseased valve is left in place and the current implant technique
still has some limitations, the transcatheter aortic valve implan-
tation (TAVI), both transapical and transfemoral, still carries few
drawbacks such as paravalvular leakages, increased pacemaker
rates, stroke, vascular complications, and reembolization.5 Fur-
thermore, transapical TAVI remains a surgical procedure with
similar surgical trauma as compared to minimally invasive ap-
proaches,6whereas the crimping procedurewith TAVI technology
may even jeopardize the durability of the prosthesis.7 In order
to provide a curative treatment to patients ‘‘in the grey zone’’ of
medium to intermediate high risk8Y10 and to fill the gap between
TAVI and traditional AVR replacement, sutureless and rapid de-
ployment valves have been introduced to facilitate safe and ef-
fective implantation of aortic biological valve prostheses in a rapid
fashion using modern deployment techniques.11,12
To reduce the pitfalls of sternotomy in aortic valve re-
placement, minimally invasive approaches using either minister-
notomy or right anterior minithoracotomy have been introduced,
and safety and efficacy have been confirmed in a propensity
score matched analysis13 and one review.14 However, owing to
longer cross-clamp times and cardiopulmonary bypass times
caused by the higher grade of complexity of the procedure,15
these approaches did not gain wide popularity, although even
the use of various pericardial and porcine stentless valves
proved to be possible through ministernotomy.16 Meanwhile,
the Perceval Sutureless valve (Sorin/LivaNova Group, Saluggia,
Italy), the EDWARDS INTUITY Elite (Edwards Lifesciences,
Corp, Irvine, CA USA), and the Medtronic 3F Enable
Bioprosthesis (Medtronic, Inc, Minneapolis, MN USA) have
proven their suitability for different minimally invasive ap-
proaches to reduce aortic cross-clamp time in a prospective,
nonrandomized trial17 and one prospective randomized study,18
thus reducing perioperative risk of the patients in nonrandomized
trials.19,20 A recent systematic review and meta-analysis on
12 studies using Perceval Sutureless valve,Medtronic 3FEnable,
or EDWARDS INTUITY confirmed that sutureless aortic valve
implantation is a safe procedure associated with shorter cross-
clamp and cardiopulmonary bypass time compared to conven-
tional approaches.21 Sutureless and rapid deployment aortic valve
replacement, furthermore, was associated with lower 30-day mor-
tality and lower risk of postoperative aortic regurgitation compared
to transapical TAVI in a multicenter, propensity-matched analysis22
and improved survival up to 24 months23 compared to TAVI, re-
spectively. Compared to the implantation of stented valves, the use
of Perceval sutureless valve in retrospective analyses resulted in
shorter procedural times24 associated with better clinical outcomes
as measured by blood transfusions, shorter intensive care unit stay,
ventilation time, postoperative atrial fibrillation, pleural effusions,
respectively, and reduced hospital costs by approximately 25%.25
Yet, no guidelines exist to define which patients might
take profit from less invasive procedures in the therapy of aortic
valve stenosis. The aim of the project was to gain evidence-based
consensus on the use of sutureless and rapid deployment valves
in minimally invasive isolated aortic valve replacement, and to
define the role of minimally invasive aortic valve replacement
with sutureless and rapid deployment valves.
METHODS
Three approved sutureless and rapid deployment valves
with specific features of design and implantation technique
were included in the literature search and the panel process.
Perceval Sutureless Valve
The Perceval sutureless valve (Fig. 1) represents a truly
sutureless aortic valve prosthesis. It comprises a biological
component of bovine pericardium treated to reduce the risk of
calcification, and a self-expanding and elastic nitinol alloy stent,
covered by a thin coating of carbofilm for improved biocom-
patibility. The stent consists of 2 rings, as well as 9 connecting
struts, with the dual task of supporting the valve and holding it in
place with no need for any permanent suture. The stent adapts to
the anatomy of the aorta and follows its movements, relieving the
stress on the leaflets and enhancing valve durability. For im-
plantation, the valve is collapsed with an atraumatic device
compression, assuring that the valve leaflets are not affected.
Perceval is lowered until the correct position while collapsed,
enhancing direct visualization, and then self-expands back to its
original diameter. Ballooning is recommended by the manu-
facturer to optimize adherence to the native aortic wall.
EDWARDS INTUITY
The EDWARDS INTUITY Elite valve (Fig. 2) is a stented
trileaflet bovine pericardial bioprosthesiswith a balloon-expandable
cloth-covered skirt frame at the inflow aspect represent-
ing rapid deployment valve prosthesis. For implantation,
3 equidistant figure-of-eight or mattress guiding sutures are
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placed through the annulus at the nadir of each sinus and then
passed through the corresponding black marks on the nadir
portion of the valve suture ring. The valve is positioned into the
aortic annulus by use of the guide sutures and 3 tourniquets, with
the stent and polyester sealing cloth being seated directly below
the aortic annulus. A thoracoscope can be occasionally inserted
through the holding device to confirm proper positioning. Once
the valve is properly seated, the balloon-expandable frame is
deployed with short balloon inflation. The guiding sutures are
finally tied.
Medtronic 3F Enable Bioprosthesis
The 3f EnableModel 6000 valve (Fig. 3) as another rapid
deployment valve prosthesis is made with a stentless valve of
3 equal sections of equine pericardial tissue sewn in a self-
expanding nitinol support frame. The nitinol frame is intended
to maintain the tissue valve geometry, optimize its flow area, and
eliminate the potential for misplaced attachment of the com-
missural tabs. The properties of nitinol and the flexibility of the
equine pericardial leaflets allow the device to be folded in chilled
water and positioned appropriately within minutes intraopera-
tively. On deployment, its shape and size return to the preset
dimensions and the outward radial forces keep the valve fixed at
the target position. For implantation, a single guiding suture was
recommended to support placement of thevalve at the level of the
annulus. The polyester flange at the inflowaspect promotes tissue
ingrowth, thus contributing to the long-term stabilization of the
valve. However, after some cases of migration, the company is
now recommending to use 2 permanent sutures.
Literature Search Strategy and Selection Criteria
Literature search was performed fromApril to November
2014. To be eligible for the review, studies should evaluate the use
of sutureless or rapid deployment valves in isolated aortic valve
replacement facilitated byminimally invasive approaches.Articles
were identified via an electronic search on PubMed, Embase, and
Cochrane Library. We used the following keywords: ‘‘aortic
valve replacement’’ and ‘‘minimally invasive’’ and ‘‘sutureless‘‘
or ‘‘rapid deployment’’ in our search.We also performedmanual
search for the articles in the reference. We only searched studies
that were published in English. Abstracts and unpublished
studies were excluded. If the author reported results that were
obtained on the same patient population in several studies, we
would use the most recent or complete study. Besides clini-
cal studies, relevant guidelines published since 2006, with
their latest version if they had undergone substantial revision,
were included.
Two independent scientists performed a full-text anal-
ysis with the emphasis on selection of main topics to represent
possible recommendations on the use of minimally invasive
approaches in isolated aortic valve replacement in general and
FIGURE 1. Perceval sutureless valve. Reprinted from
Barnhart et al. Current clinical evidence on rapid deployment
aortic valve replacement: sutureless aortic bioprostheses.
Innovations. 2016;11:7Y14.
FIGURE 2. EDWARDS INTUITY. Reprinted from Barnhart et al.
Current clinical evidence on rapid deployment aortic valve
replacement: sutureless aortic bioprostheses. Innovations.
2016;11:7Y14.
FIGURE 3. Medtronic 3F Enable bioprosthesis. Reprinted from
Barnhart et al. Current clinical evidence on rapid deployment
aortic valve replacement: sutureless aortic bioprostheses.
Innovations. 2016;11:7Y14.
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the indications, benefits, possible pitfalls, contraindications,
perioperative conditions, complications and their treatment,
outcome and follow-up criteria for the use of sutureless and
rapid deployment valves in minimally invasive approaches.
These selected main topics represented the basic material for
the first round of the Delphi process.
Panel of Experts
The selection of panel experts should reflect the popu-
lation of cardiac surgeons involved both in minimally invasive
aortic valve replacement and the use of sutureless and rapid
deployment valves for use in aortic position. For this purpose, a
Wsnowball samplingW approach was used, starting with a pre-
liminary list of possible experts, defined by credibility to the target
audience of cardiac surgeons considering the use of sutureless
valves and rapid deployment valves in aortic valve replacement. A
steering committee (M.G., T.A.F., B.M., T.F.M.F., and B.G.)
identified and rated possible candidates according to the following
criteria. Possible credibility was defined by recent activities on
the mentioned topics by (1) publication of scientific papers
(studies, reviews) with frequent citations, (2) playing an active
role in guidelines committees, and (3) representing speaker on
recent congresses of relevant scientific societies, respectively.
Additional possible experts were included to the preliminary list
if recommended by one of the final experts.
From the preliminary list, experts were contacted for
further participation according to their current clinical expertise.
Only experts with an experience of at least 100 cases undergoing
minimally invasive aortic valve replacement (excluding all cases
of transfemoral or transapical aortic valve implantation) and
at least 50 of the minimally invasive cases using sutureless or
rapid deployment aortic valve prostheses were chosen. All ex-
perts had to declare any conflicts of interest before final con-
stitution of the panel.
Outcomes had to be reported according to the recom-
mendations of the American Association for Thoracic Surgery,
The Society of Thoracic Surgeons, the European Association
for Cardio-Thoracic Surgery,26 and the Valve Academic Re-
search Consortium.27
Panel Process
After selection of experts, in a first round they were asked
to rate the main topics to be included in the consensus selected
from literature review. Experts were asked to discard or add
topics not represented yet and to give further details on each
main topic to prepare panel discussion during second round.
First round was performed from July to September 2014
electronically. Main topics were included if mentioned to be
relevant by at least one of the experts and excluded if discarded
by all experts. The second round represented a meeting of the
expert panel which took place October 10, 2014. Each main
topic that was rated as relevant during first round, was presented
with evidence based recommendations and major clinical re-
sults if published, and then intensively discussed with regard
to their eligibility as general recommendations for cardiac
surgeons to give decision criteria for the use of sutureless and
rapid deployment valves in isolated aortic valve replacement. A
writing committee prepared the recommendations for final
discussion through a third electronic round including literature
and evidence screening, and finally wrote the manuscript.
RESULTS
Literature Search
The search model could retrieve a total of 6,025 publi-
cations covering a wide range of medical fields. After title and
abstract screening and final full text analysis a total of 43 papers
covering 33 clinical trials and 9 systematic reviews were iden-
tified (Table 1). However, no guidelines on the use of sutureless
and rapid deployment valves in minimally invasive aortic valve
replacement could be identified as presumed. Additional 25 pa-
pers describing the results of clinical studies were included from
hand search resulting a total of 68 papers to be included.
Results of Delphi Panel and Expert
Panel Discussion
A total of 28 international experts fulfilling the criteria of
at least 100 cases using minimally invasive approaches for
aortic valve replacement, in particular minithoracotomy and
partial sternotomy, and at least 50 of these minimally invasive
cases using sutureless or rapid deployment aortic valve pros-
theses were selected during selection process to take part in all
panel rounds. After the first round a total of 24 possible main
topics were prepared for the discussion during the second panel
round. After discussion and final electronical round, the experts
identified a total of 12 recommendations for the use of
sutureless and rapid deployment valves in minimally aortic
valve replacement were identified by the experts (Table 2).
DISCUSSION
The experts identified a variety of benefits for the use of
sutureless and rapid deployment valves in case of aortic valve re-
placement as compared to pericardial, stented, and stentless valves
using conventional surgical approaches, and transfemoral and
transapical TAVI, respectively. Additionally, a number of benefits
compared to stented biological valves using minimally invasive
approaches could be identified,which is themain focus of this paper
and of this panel with expertise on minimally invasive procedures.
A recent meta-analysis21 has shown how observational
evidence suggests that sutureless aortic valve implantation is
not only a safe procedure associated with shorter cross-clamp
TABLE 1. Results of Literature Search
Clinical
Trials Guidelines
Systematic
Review All
Search terms
- Aortic valve replacement (A) 991 18 16 1,025
- Minimally invasive (B) 3,213 91 1,488 4,792
- Sutureless (C) 141 V 19 160
- Rapid deployment (D) 27 V 21 48
Total 4,372 109 1,544 6,025
Search model
- Terms A and B and (C or D) 33 V 9 43
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and CPB duration, and comparable complication rates to the
conventional approaches, but also facilitates minimally invasive
approaches.
Diagnostics and Patient Selection
The indication and contraindication for sutureless and rapid
deployment valves first of all follow the general recommendations
for the choice of biological stented prostheses in aortic valve re-
placement, according to the current guidelines.2,28 Since current
recommendations focusonpatients at an age of 65years or older to
be candidates for biological valve replacement, the experts also
recommend to consider sutureless and rapid deployment valves for
patients older than 65 years.
The experts identified a high standard of preoperative
imaging as a central precondition for proper patient selection
and procedure planning, which should be applied the sameway
as for TAVI procedures. Therefore, a computed tomographic
(CT) scan providing sufficient resolution with expertise in the
interpretation is recommended besides the classical diagnostics
as transthoracic echocardiography and coronary angiography
used to verify the indication, and exclude patients with addi-
tional cardiac pathologies requiring a different surgical ap-
proach. This way the ascending aorta can be displayed, and a
proper planning of aortotomy with respect to annular diameter
can be performed, as well as a proper size estimate and a closer
analysis of the extent of calcification of the ascending aorta.29
Additionally, the CT scan is useful for the location of coronary
ostia, the definition of the aortic root geometry, especially with
respect to the relation between aortic annulus and sinotubular
junction, for the identification of the type of bicuspid valve, if
present, and for the positioning of the aortic root in relation to
the sternum and the second right intercostal space. In case of
renal failure or allergies to contrast media, native CT scan30 or
reduced dosage of contrast media31 may be sufficient for most
scenarios. The location of calcifications in the aortic root wall
may affect the choice of the sutureless prosthesis, since, for
instance, the Edwards Intuity requires a hockey stick incision
that goes deep to the noncoronary sinus.32
The experts identified annulus sizes of less than 19 mm
as too small for the implantation of sutureless and rapid de-
ployment valves, since owing to size limits of the current
available prostheses, annulus enlargement procedures would be
necessary. Those procedures can be done using most minimally
invasive approaches, thanks to full access to the aortic root and
subvalvular structures.33 However, since these procedures may
be time consuming and the implantation of patch material in the
aortic annulus may result in less stability to anchor a self-
expanding valve, root enlargement procedures should be
avoided if sutureless or rapid deployment valves are consid-
ered. On the other hand, since available prostheses are limited
to an annular size of 27 mm and since no suture material on the
annular level might reduce annulus size, the use of sutureless
and rapid deployment valves currently is limited to annular
sizes of 19 to 27 mm. Since multislice CT may overestimate the
annulus diameter, 3-dimensional transesophageal echocardi-
ography may help for preprocedural evaluation.34 However,
even with preoperative CT scan, additional intraoperative
sizing is necessary after thorough resection of the native cal-
cified aortic valve and decalcification of the aortic annulus. In
case of degenerative aortic regurgitation with annuloaortic
ectasia, the experts recommend not to use a sutureless or rapid
deployment valve to prevent valve migration.
Bicuspid valves are contraindicated if no raphe (type
0 according to Sievers et al35) is present; in case of type 1 bi-
cuspid valve with one raphe, sutureless and rapid deployment
valves can be used if coronary ostia are not in a 180-degree
position and the annulus is circular after decalcification; like-
wise, type 2 bicuspid valve with 2 raphes are indicated if the
2 commissures have approximately the same height.
Since only case reports describe the potential use of
sutureless and rapid deployment valves and according to the
recommendations of current guidelines2,28 the panel experts do
not recommend the use of sutureless valves in extensive en-
docarditis with annular abscess or destruction since usually
defects in the aortic root or annulus remain even after proper
debridement of the infected structures.
To verify proper systolic and diastolic function of
the implanted valve and to verify left ventricular wall motility
reflecting unchanged coronary perfusion, intraoperative
transesophageal echocardiography (TEE) is useful in all
cases of sutureless and rapid deployment valves irrespective
of the personal experience and the surgical approach, also
according to the current recommendations for TAVI.36
Transesophageal echocardiography should be started be-
fore induction of cardiopulmonary bypass with docu-
mentation of valve pathology, ventricular function, and
associated valve pathologies and must be performed both
TABLE 2. Recommendations of Experts for the Implantation
of Sutureless and Rapid Deployment Valves in Minimally
Invasive Aortic Valve Replacement After Second Round of
the Panel Process
Recommendation
1. Use of sutureless and rapid deployment valves together with minimally
invasive approaches in patients requiring biological valve replacement
and not serving as candidates for TAVI
2. Use of sutureless and rapid deployment valves are recommend in order
to reduce extracorporeal circulation and aortic cross-clamp time
3. Suitable annular sizes (after decalcification) of 19 to 27 mm
4. Oversizing with sutureless valves is not beneficial and can have
negative impact
5. Contraindication for annular abscess or destruction due to
infective endocarditis
6. Contraindication for bicuspid valve type 0
7. Implantation possible in bicuspid valves type 1 and 2 if
a. coronary ostia do not have 180-degree position,
b. round annulus, and
c. uniform height of the commissures (type 2).
8. Use of sutureless and rapid deployment valves reduces early complications
as prolonged ventilation, blood transfusion, atrial fibrillation, pleural
effusions, paravalvular leakages and aortic regurgitation, and renal
replacement therapy, respectively
9. Use of sutureless and rapid deployment valves results in reduced ICU and
hospital stay
10. Use of sutureless and rapid deployment valves will lead to a higher
adoption rate of minimally invasive approaches in aortic valve replacement
11. Take respect to necessary, brief learning curves for both sutureless and
minimally invasive programs
Innovations & Volume 11, Number 3, May/June 2016 Sutureless Valves and Minimally Invasive Surgery
Copyright * 2016 by the International Society for Minimally Invasive Cardiothoracic Surgery 169
during weaning from cardiopulmonary bypass and at the
end of the operation.37
Surgical Approach and Valve Prosthesis Selection
The first reports on minimally invasive aortic valve re-
placement have been published almost 20 years ago by different
groups, using upper or right-sided partial sternotomy33,38 or
parasternal minithoracotomy,39 respectively. The primary aim
was to avoid full sternotomy to reduce surgical trauma, improve
patient comfort, and reduce postoperative ICU and hospital stay
to lower costs in a retrospective study.40 However, in contrast to
minimally invasive coronary artery bypass grafting, which was
also introduced to avoid extracorporeal circulation, the main
benefit ofminimally invasive approaches in cardiac valve surgery
remained in less pain and thus improved patient comfort,41
postoperative ventilation time,42,43 and a significant reduction of
blood transfusion requirements44 in 2 propensity scoreYmatching
studies and 1meta-analysis.A series of 1,639patients over 16 years
could demonstrate benefits, especially for patients undergoing
reoperations and for those older than 80 years.42 Despite these
benefits, partial sternotomy and parasternal thoracotomy as ap-
proach for aortic valve replacement did not reachwide popularity
owing to concerns on limited access.
However, the experience with central cannulation via
minimally invasive approaches both in aortic and mitral valve
surgery facilitated other minimally invasive approaches as right
minithoracotomy, for example, in the second intercostal space,
with optimal exposure of the aortic root and annulus45 The use
of pericardial stentless valves for subcoronary implantation
technique was shown to be possible via partial sternotomy.16
Compared to full sternotomy, the right anterior thoracotomy
could prove lower incidence of postoperative atrial fibrillation
and blood transfusion, and shorter ventilation time and hospital
length of stay in nonrandomized but propensity scoreYmatched
trials.13,46 Even in case of prior median sternotomy, the right
minithoracotomy as approach for redo aortic valve replace-
ment could show benefits with regard to shorter ICU and total
hospital stays, along with lower morbidity, and a trend toward
lower mortality in retrospective analysis.47 Additionally, com-
pared to ministernotomy, right minithoracotomy featured bene-
fits in retrospective analyses with regard to lower postoperative
complication rates, shorter hospital stay48 and hospital costs,49
respectively.
As a next step, the successful use of sutureless valves could
be demonstrated via partial sternotomy in a nonrandomized
multicenter study50 and with even better surgical access via right
anterior minithoracotomy.51 The latter approach serves as an
alternative for high-risk patients to facilitate full decalcification
of the aortic annulus.52 Excellent hemodynamic results, post-
operative outcome, and 1-year survival of 90% were recently
demonstrated.20 A recent propensity-matched analysis could
also show the advantage of standard diseased valve removalwith
shorter procedural times, resulting in the recommendation that
minimally invasive sutureless aortic valve replacement may be
the first-line treatment even for high-risk patients considered in
the ‘‘gray zoner’’ between TAVI and conventional surgery.8
All the experts highly recommend the use of sutureless
and rapid deployment valves together with minimally invasive
approaches for isolated aortic valve replacement in patients
requiring biological valve replacement, which are not candi-
dates for transfemoral or transapical TAVI according to the
current guidelines.
However, a specific learning curve is necessary for all
sutureless valves, regardless of the prosthesis model53,54 and the
minimally invasive approach.55Y57 Therefore, the experts recom-
mend proper education and proctoring by experienced surgeons
for the introduction of both programs to avoid complications.
There is no recommendation on the use of specific sutureless
or rapid deployment valves; however, the experts identified
specific conditions of the current available rapid deployment
valve prostheses with respect to the aortotomy and possible
impact on the selection of the surgical approach during the
second round of the panel process, which might be taken into
consideration when planning the procedures. All the sutureless
and rapid deployment valve prostheses are designed to target a
less traumatic procedure with regard to aortic root structures.
The EDWARDS INTUITY Elite has the advantage to
require an aortotomy close to the annulus in the noncoronary
sinus; this facilitates better access and decalcification of the
annulus, but it is not collapsible.
The Perceval Sutureless valve requires a bit higher
aortotomy but can be fully collapsed for implantation for
atraumatic insertion.
The Medtronic 3F Enable Bioprosthesis, owing to its
higher profile, requires a much higher aortotomy but is foldable
for its implantation for atraumatic insertion.
Extracorporeal Circulation and Cross-clamp Time
Most concepts in aortic valve replacement, which in-
cludes resection of diseased valves and decalcification of the aortic
annulus, use extracorporeal circulation, aortic cross-clamping, and
myocardial protection. Compared to transfemoral and transapical
TAVI, the main benefits of sutureless valves can be found in
creating a round, smooth annulus to safely fix a valve prosthesis
with maximal orifice area, almost without the risk of paravalvular
leakage, migration, or damage to conduction system and coronary
ostia. However, these mostly conventional approaches carry the
well-known risks of myocardial infarction due to insufficient
myocardial protection, and systemic inflammatory response syn-
drome due to the extracorporeal circulation system. Reduced
cross-clamp and extracorporeal circulation times may lower both
risks.57 Sutureless and rapid deployment valves carry the po-
tential to shorten cross-clamp time, resulting in significantly
shorter procedural times compared to standard conventional
valve prostheses in both conventional and minimal invasive24,25
surgical approaches. The experts therefore recommend the use
of sutureless and rapid deployment valves in each case, with
the necessity to reduce extracorporeal circulation and aortic
cross-clamp times.
Postoperative Course
The experts found evidence for reduced ICU and
hospital stay25 after the use of sutureless valves from different
propensity-matched score analyses compared to standard con-
ventional aortic valve prostheses or TAVI.52 Since postoperative
complications contribute to prolongation of both ICU and hospital
stay, the experts identified reduced ventilation times,19,25 reduced
blood transfusion rates, and lower incidence of atrial fibrillation
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and pleura effusions,25 as possible reasons for improved overall
outcome. Transcatheter aortic valve implantation patients showed
paravalvular leakages more frequently than sutureless and rapid
deployment valves8; recent studies, however, suggest a decrease of
transvalvular regurgitation58 and paravalvular leakages59 with
modified design. Multivariate analysis showed sutureless aortic
valve replacement to have a not statistically significant protective
effect against aortic regurgitation, pacemaker implantation, and
renal replacement therapy as comparedwith transapical TAVI.60A
multicenter study with retrospective analysis of 314 patients
demonstrated 1-year survival of 90.5%, and freedom from valve-
related mortality, stroke, endocarditis, and reoperation of 99.0%,
98.1%, 99.2%, and 98.3%, respectively.61 At a 24-month
follow-up, overall survival free from major adverse cardiac
and cerebrovascular events and prosthetic regurgitation was
significantly better (P G 0.05) after sutureless valve implantation
(91.6% T 3.8%, n = 53) than after TAVI (70.5 T 7.6%, n = 55).23
Owing to the lack of long-term studies for sutureless and fast
deployment valves with innovative stent designs, no recom-
mendation for late outcome with respect to valve durability may
be given, but the current results are promising. So far, 5-year
results of the Medtronic 3F Enable bioprosthesis and of the
Perceval sutureless valve showed excellent results in hemody-
namics and freedom from structural valve deterioration. For
Medtronic 3F Enable bioprosthesis in 141 patients at 5 years62
and for Perceval in a cohort ofmore than 700 patientswith 5 years
of follow-up coming from 3 consecutive clinical trials recently
presented by Prof. Shrestha during EACTS 2014, freedom from
structural valve deterioration reported was 100%. The longest
published follow-up for theEdwards Intuity valve is of 3 years, in a
cohort of 287 patients,63 with no cases of structural valve de-
teriorations reported.
However, there is no proof for any effect of minimally
aortic valve surgery on durability. The experts recommend the
use of sutureless and rapid deployment valves in order to re-
duce perioperative and medium term morbidity. Owing to re-
duced morbidity, also postoperative ICU and total hospital stay
may be reduced.
The experts found no evidence and could therefore give
no recommendation for the effect of sutureless and rapid de-
ployment valves in minimally invasive surgery with regard
to overall mortality, prosthetic valve endocarditis, or other
hospital-acquired infections. Reduced wound infections, es-
pecially the complete avoidance of deep sternal wound in-
fections, and reduced rate of mediastinitis are apparently
linked to the approach of right anterior minithoracotomy and
not to the use of sutureless valves.
CONCLUSIONS
In conclusion, sutureless and rapid deployment valves
overcome most of the previous limitations in minimally aortic
valve replacement, in particular, prolonged cross-clamp times,
owing to limited access in partial sternotomy. Sutureless and
rapid deployment valves by their design deliver comparable
hemodynamic results as stentless valves. Starting a program
for approaching minimally invasive aortic valve replacement
should as a first step include partial sternotomy and then,
after reaching sufficient individual and institutional expertise,
include right anterior minithoracotomy. With a short learning
curve, which has to be taken into account when starting a
program in this stepwise fashion, the implantation of sutureless
valves via a minimally invasive approach is an easy and safe
procedure. Reducing cross-clamp times and enabling the im-
plantation via limited access the use of sutureless and rapid
deployment valves overcomes most of the previous limitations
in minimally invasive aortic valve replacement. In the future,
this will result in a higher adoption rate of minimally invasive
techniques for many surgeons, leading to more patient comfort,
shortening of hospital stay, and even reduction of costs de-
pending on the reimbursement system. Additionally, by using
sutureless aortic valves, the individual surgeon’s skills do not
represent as critical factors for the safety and efficacy in mini-
mally invasive aortic valve replacement. The international ex-
perts recommend sutureless aortic valve replacement together
with minimally invasive approaches for eligible patients re-
quiring biological valve replacement.
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